The next generation of healthcare
Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. We have been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA approval and other major certificates worldwide for our innovative solutions.
The next generation of healthcare
Created as a spin-off of the Italian National Research Council, Echolight is at the forefront of medical innovation, introducing new cutting-edge solutions to contribute to human wellbeing. We have been awarded all the standard certificates: UNI CEI EN ISO 13485: 2016, Quality Management System UNI EN ISO 9001: 2015, CE mark, FDA approval and other major certificates worldwide for our innovative solutions.
2010
Start
Echolight srl was officially incorporated by the founding team with a revolutionary idea: developing the first radiation-free device for early diagnosis of osteoporosis at the lumbar vertebrae and the femoral neck.
Patent
Viene ufficialmente depositato il primo brevetto della tecnologia R.E.M.S.: innovativo approccio ecografico per la caratterizzazione della micro-architettura ossea.
2011
Life Science Capital
Life Science Capital S.p.a., an italian investment company in the medical device sector, invests in Echolight to support and speed up the research and development activities of the company.
EchoS
The first version of Echos is finalized: the only radiation free device for bone densitometry at the lumbar vertebrae and the femoral neck. A decisive step towards a new era in the early diagnosis of osteoporosis and bone health assessment.
2012
2013
Clinical trials
In collaboration with the National Council of Research the first multi-center study for the clinical validation of R.E.M.S. technology in the most important reference centers for the diagnosis of osteoporosis is launched.
Certifications
Echolight ottiene tutte le certificazioni standard: UNI CEI EN ISO 13485: 2012, ISO 13485: 2003, UNI EN ISO 9001: 2008 Sistema di gestione della qualità e il marchio CE per Echos, EchoStation ed EchoStudio di KIWA CERMET.
2014
2015
Premiere
Echolight introduces to the international medical community the latest release of Echos at the World Congress of Osteoporosis.
Round A
Panakès and Invitalia Ventures have co-led an investment round in Echolight, in order to support the clinical validation of the innovative technology and the worldwide launch of the product.
2016
Advisory Board
Echolight established the new international scientific advisory board with the most important medical personalities in the diagnosis of osteoporosis.
2017
Market Launch
Echolight at the International Trade Fair MEDICA launched Echos after extensive research and development activities carried out over the last eight years.
FDA Clereance
Echolight S.p.A. has received 510(k) clearance from the Food and Drug Administration (FDA) to market its range of products in the U.S.A.
2018
Multicenter Study
Milestone pubblication on Osteoporosis International about R.E.M.S. Multicenter Clinical Trial: “Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck.
Consensus Paper
Echolight obtained a Consensus Paper from ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, on R.E.M.S. technology.
2019
Echolight around the globe
Echolight in less than three years has a sales network of 40 distributors and several hundred satisfied customers all over the world.
2020
Echolight USA
Echolight announces the opening of a new corporate headquarters in the United States located in Seattle.
R.E.M.S. in the guidelines
R.E.M.S. technology recommended in the guidelines for fragility fractures risk assessment.
2021
Scientific Advisory Board
As regards diagnosis of osteoporosis and related bone diseases, the most prestigious personalities of the world scientific community have chosen EchoS and share their thoughts on their experience using R.E.M.S. technology. The clinical validation of proprietary technology was carried out in the most prestigious centres of reference for the diagnosis of osteoporosis worldwide, with several multicentre studies that involved more than 10,000 subjects.
Prof. Maria Luisa Brandi
Director of Bone Mineral and
Metabolism diseases Unit at
Careggi Hospital in Florence.
Prof. of Endocrinology
Univeristy of Florence.
Prof. Jean-Yves Reginster
ESCEO President
Head of the bone and
cartilage, Metabolism Unit.
University of Liegi
Liegi, Belgium.
Prof. Cyrus Cooper
IOF President
Professor of Rheumatology
University of Southampton
Southampton General Hospital
United Kingdom
Prof. Adolfo Diez-Perez
Department of
Internal Medicine.
Hospital del Mar
Barcelona University
Barcelona, Spain
Prof. René Rizzoli
Emeritus Professor of Medicine
University Hospitals and
Faculty of Medicine.
Geneva University
Switzerland
Prof. Bernard Cortet
President of the GRIO
Scientific Board of Paris.
Professor in Rheumatology
Roger Salengro Hospital
Chu de Lille, France.
Echolight around the globe
Echolight was established in Italy with head office in Lecce. In 2020, Echolight opened its offices also in the United States (Seattle) and in less than three years, it already has a sales network with more than 40 distributors and several hundreds of satisfied customers across the world who have adopted the innovative R.E.M.S. technology for assessing the bone condition of their patients.
Echolight S.p.a.
Viale Cipro, 6
73100 Lecce – Italy
+39 0832 159 26 07
US Headquarters
509 Madison Ave RM 1510
New York, New York 10022, USA
Copyright © 2021 - Echolight S.p.a
